Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells

Journal of Neuro-Oncology

Volumn 123, Issue 2, 2015, Pages 217-224

  Alexiou, George A ^a   Tsamis, Konstantinos I ^a   Vartholomatos, Evrysthenis ^a   Peponi, Evangelia ^b   Tzima, Eftychia ^b   Tasiou, Ifigeneia ^b   Lykoudis, Efstathios ^a   Tsekeris, Pericles ^b   Kyritsis, Athanasios P ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

DFMO; Glioma; Radiation; TRAIL

Indexed keywords

ANNEXIN; CASPASE 8; EFLORNITHINE; PROTEIN BAD; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TNFSF10 PROTEIN, HUMAN;

A172 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CHEMORADIOTHERAPY; CONTROLLED STUDY; D54 CELL LINE; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; GLIOBLASTOMA; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; T98G CELL LINE; TARGET CELL DESTRUCTION; U251MG CELL LINE; BRAIN NEOPLASMS; CELL ADHESION; CELL MOTION; DRUG EFFECTS; FLOW CYTOMETRY; GLIOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL CULTURE; WESTERN BLOTTING; X RAY;

APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COMBINED MODALITY THERAPY; EFLORNITHINE; FLOW CYTOMETRY; GLIOMA; HUMANS; RADIATION DOSAGE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; X-RAYS;

EID: 84930374879     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1799-9     Document Type: Article

References (28)

1. Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G et al (2010) Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol 28:2467–2474
2. Alexiou GA, Goussia A, Voulgaris S, Fotopoulos AD, Fotakopoulos G, Ntoulia A, Zikou A, Tsekeris P, Argyropoulou MI, Kyritsis AP (2012) Prognostic significance of MRP5 immunohistochemical expression in glioblastoma. Cancer Chemother Pharmacol 69:1387–1391
3. Alexiou GA, Tsamis K, Kyritsis AP. Targeting tumor necrosis factor–related apoptosis-inducing ligand (TRAIL): a promising therapeutic strategy in gliomas. Semin Pediatr Neurol. (in press) doi:10.1016/j.spen.2014.12.002
4. Tsamis KI, Alexiou GA, Vartholomatos E, Kyritsis AP (2013) Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24. Cancer Invest 31:630–638
5. Verbrugge I, de Vries E, Tait SW, Wissink EH, Walczak H, Verheij M, Borst J (2008) Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 27:574–584
6. Kim MR, Lee JY, Park MT, Chun YJ, Jang YJ, Kang CM, Kim HS, Cho CK, Lee YS, Jeong HY, Lee SJ (2001) Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett 505:179–184
7. Ueda A, Araie M, Kubota S (2008) Polyamine depletion induces G1 and S phase arrest in human retinoblastoma Y79 cells. Cancer Cell Int 21(8):2
8. Laukaitis CM, Gerner EW (2011) DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25:495–506
9. Redgate ES, Alexander D, Magra TR, Henretty JS, Patrene KD, Boggs SS (2001) The effect of DFMO induced uptake of [3H] putrescine on human glioma cells. J Neurooncol 55:71–80
10. Tsukahara T, Tamura M, Yamazaki H, Kurihara H, Matsuzaki S (1992) The additive effect of alpha-difluoromethylornithine (DFMO) and radiation therapy on a rat glioma model. J Cancer Res Clin Oncol 118:171–175
11. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP (2005) TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233–243
12. Mitlianga PG, Sioka C, Vartholomatos G et al (2006) p53 enhances the delta-24 conditionally replicative adenovirus anti-glioma effect. Oncol Rep 15:149–153
13. Taghiyev AF, Guseva NV, Harada H, Knudson CM, Rokhlin OW, Cohen MB (2003) Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP. Mol Cancer Res 1:500–507
14. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavaré S (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110:4009–4014
15. Meyskens FL Jr, Gerner EW (1999) Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5:945–951
16. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981–990
17. Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR (2000) Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6:3878–3884
18. Terzis AJ, Pedersen PH, Feuerstein BG, Arnold H, Bjerkvig R, Deen DF (1998) Effects of DFMO on glioma cell proliferation, migration and invasion in vitro. J Neurooncol 36:113–121
19. Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS (2013) DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 42:1219–1228
20. Fong LY, Nguyen VT, Pegg AE, Magee PN (2001) Alpha-difluoromethylornithine induction of apoptosis: a mechanism which reverses pre-established cell proliferation and cancer initiation in esophageal carcinogenesis in zinc-deficient rats. Cancer Epidemiol Biomark Prev 10:191–199
21. Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL, Lee JS (2011) PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 18:666–677
22. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–162
23. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157–163
24. Kuijlen JM, Bremer E, Mooij JJ, den DunnenWF WF, Helfrich W (2010) Review: on TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 36:168–182
25. Marini P, Schmid A, Jendrossek V et al (2005) Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5:5
26. Yao KC, Komata T, Kondo Y, Kanzawa T, Kondo S, Germano IM (2003) Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg 98:378–384
27. Yount GL, Afshar G, Ries S et al (2001) Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene 20:2826–2835
28. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5:22